

Class A: ETAGX | Class C: ETCGX | Class I: ETILX | Class N: ETGLX

GILEAD FUND AT A GLANCE

Manager: Dr. Finny Kuruvilla

Fund Objective: Seeks to provide long-term capital appreciation.

About the Fund: A diversified mutual fund representing our “best ideas” for long-term capital appreciation. Historical emphases in small- and mid-cap growth, Health Care and Information Technology.

Benchmarks: S&P 500 Total Return Index, Russell Midcap Growth Index

Morningstar Category: US Fund Mid-Cap Growth

Lipper Category: Mid-Cap Growth

Net Assets: \$3.57 billion

Inception Date: July 8, 2008

REVIEW

The Eventide Gilead Fund (Class N) posted a total return of 12.40% for the third quarter of 2020, compared with the S&P 500 Total Return Index of 8.93% and the Russell Midcap Growth Index of 9.37%. The Fund (Class N) posted a total return of 42.64% for the 12 months ending 9/30/2020 compared to the S&P 500 Total Return Index of 15.15% and the Russell Midcap Growth Index of 23.23%. The reasons for the Gilead Fund’s quarterly outperformance were overweights in high-growth software and e-commerce companies that rebounded as markets recovered from COVID-19 fears.

CONTRIBUTORS

In the third quarter of 2020, the largest positive contributors to performance were Wayfair Inc, CrowdStrike Holdings Inc, The Trade Desk Inc, Fiverr International Ltd, and Five9 Inc. Wayfair saw strong momentum on revenues and profitability from the accelerated move to e-commerce due to COVID-19. CrowdStrike continued to deliver growth and profitability as end-point cybersecurity continued to be a key priority for enterprises. With advertising budgets being scrutinized more, Trade Desk has continued to execute and gain share, particularly in Connected TV. There was an acceleration in revenues and profitability as demand for Fiverr’s freelancer platform saw significant traction during a difficult pandemic period. Five9 saw continued execution in revenues and profitability with some COVID-19 related tailwinds.

Top Five Contributors ¹ (%)					Q3 2020
Company	Ticker	Sector	Average Weight	Contribution to Return	Total Return ²
Wayfair Inc	W	Consumer Discret.	4.62	1.69	47.26
CrowdStrike Holdings Inc	CRWD	Information Tech	3.41	1.09	36.92
The Trade Desk Inc	TTD	Information Tech	3.91	0.88	27.62
Fiverr International Ltd	FVRR	Communications	1.37	0.87	88.27
Five9 Inc	FIVN	Information Tech	4.12	0.67	17.18

DETRACTORS

In the third quarter of 2020, the largest negative detractors to performance were GW Pharma, Biohaven Pharmaceuticals, Smartsheet Inc, Sarepta Therapeutics Inc, and Pliant Therapeutics Inc. GW Pharmaceutical’s sub-par performance is due to commercial headwinds the company has been facing and is quite typical of performance of biotech companies in the early stages of commercialization. Biohaven’s sub-par performance is due to commercial headwinds the company has been facing (very high competitive intensity) and is quite typical of performance of biotech companies in the early stages of commercialization. Smartsheet was negatively impacted as enterprises slowed down expansion projects, leading to the company missing revenue and profitability expectations. Sarepta’s lack of recent valuation-inflecting events and positive news from competitor Pfizer Inc for their Duchenne muscular dystrophy gene therapy has pressured the stock. Pliant’s lack of recent valuation-inflecting events has pressured the stock.

Top Five Detractors ¹ (%)					Q3 2020
Company	Ticker	Sector	Average Weight	Contribution to Return	Total Return ²
GW Pharma	GWPH	Healthcare	0.71	-0.15	-20.67
Biohaven Pharmaceuticals	BHVN	Healthcare	1.18	-0.15	-11.08
Smartsheet Inc	SMAR	Information Tech	1.05	-0.16	-2.95
Sarepta Therapeutics Inc	SRPT	Healthcare	1.90	-0.24	-12.42
Pliant Therapeutics Inc	PLRX	Healthcare	1.11	-0.46	-30.22

MACRO COMMENTARY AND OUTLOOK

The post-COVID-19 rally extended as the markets, in the words of the old Wall Street saying, “climbed the wall of worry.” While COVID-19 cases increased over the summer, this was offset by optimism for a vaccine by the end of 2020. In addition, the Fed has clearly stated that it wants rates to be low for several years in order to allow for the economy to heal. During 3Q20, secular winners continued to outperform (online commerce over brick & mortar, telehealth, fintech, cloud-based software-as-a-service, etc.). We continue to utilize a three legs of the stool framework for analyzing the health of the macroeconomy. The first leg, sentiment, is neutral over

Class A: ETAGX | Class C: ETCGX | Class I: ETILX | Class N: ETGLX

long-term measures. The second leg, valuation, is showing significant historic overvaluation. However, this is offset by bonds being even more expensive. The final leg, leading indicators, is showing strength as the economy climbs out of the deep COVID-19-induced hole. Synthesizing these legs, we believe that sentiment is neutral, valuation is neutral, and the leading indicators are positive. Hence the market's rally has not been irrational. The strength and stability of the market now depends on three elements: 1) COVID-19 declining in the next few months, either from natural herd immunity or vaccine-induced herd immunity, 2) clarity on the election (a split Presidency and Senate being the market's preference), and 3) bond yields remaining low. If these are achieved, we believe the market can retain its gains.

Trailing Returns ³							30 Sep 2020
Eventide Gilead Fund	YTD	1-year	3-Year ⁴	5-Year ⁴	10-Year ⁴	Since Inception ⁴	Inception Date ⁴
Class N	29.17	42.64	21.81	18.85	18.49	16.36	7/8/2008
Class A without load	29.14	42.57	21.75	18.80	18.44	18.73	10/28/2009
Class A with 5.75% load ⁵	21.72	34.37	19.37	17.39	17.74	18.09	10/28/2009
Class C	28.38	41.53	20.85	17.91	17.54	17.82	10/28/2009
Class I	29.36	42.95	22.06	19.09	18.73	17.57	2/2/2010
Benchmarks							
S&P 500 Total Return Index ⁶	5.57	15.15	12.28	14.15	13.74	10.58	7/8/2008
Russell Midcap Growth Index ⁶	13.92	23.23	16.23	15.53	14.55	11.75	7/8/2008

Performance is historical and does not guarantee future results. Investment return and principal value will fluctuate with changing market conditions so that when redeemed, shares may be worth more or less than their original cost. Current performance may be lower or higher than the data quoted. Investors cannot directly invest in an index, and unmanaged index returns do not reflect any fees, expenses, or sales charges. The volatility of an index may be materially different than that of the Fund, and investors should not expect the Fund to achieve the same results as a listed index. Performance data current to the most recent month-end may be obtained by calling 1-877-771-EVEN (3836).

Eventide Gilead Fund total annual fund operating expenses: Class A: 1.44%; Class C: 2.19%; Class I: 1.19%; Class N: 1.39%.

1. Source: Bloomberg PORT Attribution Report. Allocation percentages are subject to change at any time, and should not be considered investment advice.
2. The total return percentage listed is impacted by the Fund's transactions and transacted price levels of the holding during the quarter.
3. The returns shown do not reflect the deduction of taxes that a shareholder would pay on fund distributions or on the redemption of fund shares. Because of ongoing market volatility, fund performance may be subject to substantial short-term changes.
4. Performance figures for periods greater than 1 year are annualized.
5. In the case of investments at or above the \$1 million breakpoint (where you do not pay an initial sales charge), a 1.00% contingent deferred sales charge ("CDSC") may be assessed on shares redeemed within eighteen months of purchase. The CDSC for these Class A shares is based on the NAV at the time of purchase. The holding period for the CDSC begins on the day you buy your shares. Some intermediaries may waive or discount the CDSC under certain circumstances.
6. The S&P 500 is an index created by Standard & Poor's of American stocks with the largest market capitalization. The Russell Midcap Growth Index measures the performance of the U.S. equity mid-cap growth segment.

The opinions expressed herein are those of the Fund's portfolio management team as of 9/30/2020 and are subject to change. There is no guarantee that such views are correct or that the outlook opinions will come to pass. Specific companies mentioned are for performance attribution informational purposes only and should not be construed as buy or sell advice. Reliance upon the views expressed herein is at the sole discretion of the reader.

Mutual funds involve risk including the possible loss of principal. Past performance does not guarantee future results. The Fund's ethical values screening criteria could cause it to under-perform similar funds that do not have such screening criteria. The Fund can invest in smaller-sized companies which may experience higher failure rates than larger companies and normally have a lower trading volume than larger companies. The Fund can have risk associated with the biotechnology and pharmaceutical industry in which these companies may be heavily dependent on clinical trials with uncertain outcomes and decisions made by the U.S. Food and Drug Administration. Companies in the technology industries have different risks including but not limited to products becoming obsolete, and entrance of competing products. Companies in the Industrial Sector carry various risks including, but not limited to, risk related to debt loads, intense competition, and sensitivity to economic cycles. The Fund can have risk related to option investing. There are special risks associated with investments in foreign companies including exposure to currency fluctuations, less efficient trading markets, political instability and differing auditing and legal standards. The Fund can invest in private companies. Private investments include various risks including but not limited to lack of liquidity, capital commitment risk, and valuation risk. Private companies may not be financially profitable and have uncertain futures, subjecting them to additional risks.

Investors should consider a fund's investment objectives, risks, charges and expenses carefully before investing or sending money. This and other important information can be found in the prospectus, which can be obtained at <https://www.eventidefunds.com/prospectus> or by calling 1-877-771-EVEN (3836). Please read the prospectus carefully before investing. Eventide Mutual Funds are distributed by Northern Lights Distributors, LLC, Member FINRA/SIPC, which is not affiliated with Eventide Asset Management, LLC.